SECTM1

SECTM1 (K12) is a type I transmembrane glycoprotein that localizes to the Golgi apparatus and also generates a soluble secreted isoform from its N-terminal domain (PMID:9480746). It functions as a costimulatory ligand for the lymphocyte receptor CD7, directly binding CD7 on T and NK cells to promote T cell proliferation, IFN-γ and IL-2 production (synergizing with CD28 signaling), and NK cell activation (PMID:10652336, PMID:22184754). SECTM1 expression is induced by IFN-γ through a STAT1-dependent pathway in monocytes and dendritic cells, establishing a positive feedback loop linking innate cytokine signals to adaptive T cell costimulation (PMID:22184754).

1. 1998 High

   Identification of SECTM1 as a novel Golgi-resident transmembrane protein with a secreted isoform established its basic topology and suggested both intracellular and extracellular functions.

   Evidence Immunofluorescence colocalization with Golgi markers, detergent/high-pH extraction fractionation, and detection of a ~20 kDa secreted form in conditioned medium of transfected cells

   PMID:9480746

   Open questions at the time

   • No receptor or binding partner identified
   • Biological function of the soluble isoform unknown
   • Regulation of SECTM1 expression not addressed
2. 2000 High

   Discovery that SECTM1 directly binds CD7 on T and NK cells defined the receptor–ligand pair and provided the first evidence that SECTM1 modulates lymphocyte activation.

   Evidence K12-Fc fusion protein binding by flow cytometry, co-precipitation of ~40 kDa protein from radiolabeled NK cell lysates identified as CD7 by cDNA library screening, T cell proliferation inhibition assay, and NK cell activation marker upregulation

   PMID:10652336

   Open questions at the time

   • Structural basis of SECTM1–CD7 interaction not determined
   • Whether the membrane-bound or soluble SECTM1 isoform mediates CD7 engagement in vivo is unresolved
   • Downstream signaling pathways in lymphocytes upon CD7 ligation not characterized
3. 2011 High

   Demonstration that SECTM1 costimulates both CD4 and CD8 T cells in a CD7-dependent manner and synergizes with CD28, together with the finding that IFN-γ induces SECTM1 via STAT1, placed SECTM1 in a positive feedback circuit linking innate and adaptive immunity.

   Evidence Recombinant SECTM1 costimulation and proliferation assays, cytokine measurements (IFN-γ, IL-2), MLR blockade experiments, and IFN-γ/STAT1-dependent induction assays in monocytes and dendritic cells

   PMID:22184754

   Open questions at the time

   • Intracellular signaling cascade downstream of SECTM1–CD7 engagement in T cells not defined
   • In vivo relevance of SECTM1 costimulation not tested in animal models of infection or immunity
   • Role of the Golgi-localized pool versus secreted isoform in antigen-presenting cell function remains unclear

• The structural basis of the SECTM1–CD7 interaction, the distinct signaling roles of membrane-bound versus soluble SECTM1, and the in vivo contribution of SECTM1 to immune responses remain undefined.
• No crystal structure or cryo-EM model of the SECTM1–CD7 complex
• No genetic loss-of-function studies in vivo
• Mechanism by which SECTM1 synergizes with CD28 at the signaling level is unknown